P53 has been strongly associated with poor chemotherapy efficacy and prognosis of AML, whereas refractory and relapsed (R/R) LSCs are largely dependent on p53 mutation inactivation (112, 123). The gene discussed is TP53; the disease is acute myeloid leukemia.